UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

VERIFY the role of initial combination therapy in patients with type 2 diabetes

The Lancet (British edition), 2019-10, Vol.394 (10208), p.1483-1485

2019

Volltextzugriff (PDF)

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

The New England journal of medicine, 2019-08, Vol.381 (9), p.841-851

2019

Volltextzugriff (PDF)

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

The New England journal of medicine, 2023-07, Vol.389 (4), p.297-308

2023

Volltextzugriff (PDF)

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

The Lancet (British edition), 2018-08, Vol.392 (10148), p.637-649

2018

Volltextzugriff (PDF)

Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A narrative review and proposed clinical approach

Diabetes, obesity & metabolism, 2022-06, Vol.24 (6), p.969-982

2022

Volltextzugriff (PDF)

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

The Lancet (British edition), 2019-01, Vol.393 (10166), p.31-39

2019

Volltextzugriff (PDF)

What is important for people with type 2 diabetes? A focus group study to identify relevant aspects for Patient-Reported Outcome Measures in diabetes care

PloS one, 2022-11, Vol.17 (11), p.e0277424-e0277424

2022

Volltextzugriff (PDF)

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Diabetes care, 2017-01, Vol.40 (1), p.69-76

2017

Volltextzugriff (PDF)

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

Diabetes, obesity & metabolism, 2022-01, Vol.24 (1), p.94-105

2022

Volltextzugriff (PDF)

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

Circulation (New York, N.Y.), 2014-10, Vol.130 (18), p.1579-1588

2014

Volltextzugriff (PDF)

Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors

Cell reports (Cambridge), 2020-07, Vol.32 (4), p.107954-107954, Article 107954

2020

Volltextzugriff (PDF)

CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries

Cardiovascular diabetology, 2021-07, Vol.20 (1), p.154-154, Article 154

2021

Volltextzugriff (PDF)

Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data

Diabetes, obesity & metabolism, 2023-10, Vol.25 (10), p.3054-3058

2023

Volltextzugriff (PDF)

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

The American heart journal, 2018-06, Vol.200, p.83-89

2018

Volltextzugriff (PDF)

Early Insulinization to Prevent Diabetes Progression

Diabetes care, 2013-08, Vol.36 (Supplement_2), p.S190-S197

2013

Volltextzugriff (PDF)

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study

Diabetes care, 2020-02, Vol.43 (2), p.468-475

2020

Volltextzugriff (PDF)

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program

Cardiovascular diabetology, 2023-03, Vol.22 (1), p.66-66, Article 66

2023

Volltextzugriff (PDF)

Efficacy of liraglutide added to sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post‐hoc analysis of LIRA‐ADD2SGLT2i

Diabetes, obesity & metabolism, 2021-10, Vol.23 (10), p.2234-2241

2021

Volltextzugriff (PDF)

Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis

Diabetes, obesity & metabolism, 2024-10, Vol.26 (10), p.4225-4240

2024

Volltextzugriff (PDF)

Diabetes and Stroke: What Are the Connections?

Journal of stroke, 2023-01, Vol.25 (1), p.26-38

2023

Volltextzugriff (PDF)

From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes

Cardiovascular diabetology, 2021-04, Vol.20 (1), p.92-92, Article 92

2021

Volltextzugriff (PDF)

Barriers to early diagnosis of chronic kidney disease and use of sodium‐glucose cotransporter‐2 inhibitors for renal protection: A comprehensive review and call to action

Diabetes, obesity & metabolism, 2024-10, Vol.26 (10), p.4165-4177

2024

Volltextzugriff (PDF)

Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial)

The American journal of cardiology, 2019-01, Vol.123 (1), p.145-152

2019

Volltextzugriff (PDF)

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

Cardiovascular diabetology, 2022-09, Vol.21 (1), p.1-172, Article 172

2022

Volltextzugriff (PDF)

DECLARE‐TIMI 58: Participants’ baseline characteristics

Diabetes, obesity & metabolism, 2018-05, Vol.20 (5), p.1102-1110

2018

Volltextzugriff (PDF)

1 – 25 von 211

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(174)
Mit Volltextzugriff
(196)

Publikationsform

Artikel
(210)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(119)
Life Sciences & Biomedicine
(118)
Humans
(88)
Diabetes
(81)
Diabetes Mellitus
(76)
Endocrinology & Metabolism
(67)
Diabetes Mellitus, Type 2 - Drug Therapy
(61)
Female
(57)
Male
(57)
Middle Aged
(44)
Diabetes Mellitus, Type 2 - Complications
(43)
Risk Factors
(38)
Aged
(37)
Antidiabetics
(35)
Cardiovascular System & Cardiology
(35)
Cardiac & Cardiovascular Systems
(33)
Cardiovascular Diseases
(33)
Kidney Diseases
(28)
Type 2 Diabetes
(28)
Clinical Trials
(23)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

VERIFY the role of initial combination therapy in patients with type 2 diabetes

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A narrative review and proposed clinical approach

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

What is important for people with type 2 diabetes? A focus group study to identify relevant aspects for Patient-Reported Outcome Measures in diabetes care

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors

CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries

Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

Early Insulinization to Prevent Diabetes Progression

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program

Efficacy of liraglutide added to sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post‐hoc analysis of LIRA‐ADD2SGLT2i

Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis

Diabetes and Stroke: What Are the Connections?

From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes

Barriers to early diagnosis of chronic kidney disease and use of sodium‐glucose cotransporter‐2 inhibitors for renal protection: A comprehensive review and call to action

Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial)

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

DECLARE‐TIMI 58: Participants’ baseline characteristics

Suchergebnisse filtern